This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ladostigil

Avraham Pharmaceuticals Ltd.

Drug Names(s): TV-3326; ladostigil hemitartrate

Description: Ladostigil Hemitartrate (TV-3326) is a novel compound with a unique approach towards the treatment of AD. It combines three mechanisms of action: MAO-inhibition, anti-acetylcholinesterase activity and neuroprotective activity. Thus, it may have both symptomatic and neuroprotective effects.

Deal Structure: Ladostigil was originally developed by three scientists: Prof. Marta Weinstock-Rosin of Hebrew University; Prof. Musa Yudaim; and Prof. Michael Chorev of Harvard University. By January 2006, Teva had acquired the exclusive world-wide license to all intellectual property related to ladostigil.

In 2007, Teva terminated its ladostigil program. Ladostigil reverted to Yissum Technology Transfer Company of the Hebrew University of Jerusalem and Technion Research and Development Foundation when Teva suspended development.

In April 2010, Yissum Research Development Company announced that it has participated in a U.S. $9 million financing of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries, Professor Marta Weinstock-Rosin and others. Yissum has also announced that, together with the Technion Research and Development Foundation (TRDF) it will exclusively license to Avraham the commercial rights of Ladostigil.


Ladostigil News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug